𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meningitis with Burkitt like B-cell lymphoma in HIV infection

✍ Scribed by R. Bomfim da Paz; H. W. Kölmel

Publisher
Springer US
Year
1992
Tongue
English
Weight
457 KB
Volume
13
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

✦ Synopsis

Malignant lymphoma with meningeal involvement was detected in 7 patients with stage IV HIV infection. The diagnosis of lymphoma was made at a maximum of four months before discovery of meningeal involvement. In our seven cases the lymphoma was B-cell type, one case expressed Kappa chains, four cases demonstrated Lambda chains and in two cases differentiation was not possible. A review of findings in all HIV positive patients treated in the same period revealed 10 non-Hodgkin lymphomas of the B-cell type, though meningeal and cerebral involvement was observed only in B-cell lymphoma of the Burkitt type.

📜 SIMILAR VOLUMES

Dose-intensified treatment of Burkitt ly
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): A comparison of two adapted BFM protocols
✍ Sudhir Tauro; Lynda Cochrane; Grete Fossum Lauritzsen; Lee Baker; Jan Delabie; C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract The chemotherapy dose‐intensity in two adapted German BFM paediatric protocols (BFM 90 and NHL 86) was compared in contemporaneously treated adults <50 years with Burkitt lymphoma and B‐cell lymphoma unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Bu

Epstein-Barr virus infection and P53 exp
Epstein-Barr virus infection and P53 expression in HIV-related oral large B cell lymphoma
✍ Anna Calzolari; Alessandra Papucci; Gianna Baroni; Giuseppe Ficarra; Berardino P 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

Background. Head and neck non-Hodgkin's lymphomas in HIV positive patients are highly related with Epstein-Barr virus (EBV) infection. In general, viral agents can alter p53 protein levels by enhancing degradation of cellular p53 or by increasing its half-life by viral protein-p53 interaction. Moreo